Going “off patent” is the fate that awaits most of the blockbuster drugs that provide pharmaceutical companies with the bulk of their profits: when the patent that protects the innovation expires, other firms can make generic “copycats” and sell them for a fraction of the price. But not all drugs are affected equally and this week’s trust, International Biotechnology, seeks to exploit the fact.

 

The Daily Telegraph – Read Article

Disclaimer

  • You are seeing this because you are accessing IBT’s website for the first time.

 

  • The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.

 

  • An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.

 

  • The material on this website is intended to be viewed only by persons resident in the EEA.

 

  • The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.

 

  • No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.

 

  • The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).